The initial treatment phase involves the administration of two medications: nivolumab and ipilimumab. These medications are given as a solution for infusion, which means they are delivered directly into the bloodstream through a vein.

During this phase, the patient receives nivolumab at a concentration of 10 mg/mL and ipilimumab at a concentration of 5 mg/mL. The specific dosage and frequency of administration are determined by the healthcare provider based on individual patient needs.

This phase lasts for a period of six months, during which the patient’s response to the treatment is closely monitored.

After completing the initial six-month treatment phase, the patient enters the randomization stage. This involves being assigned to one of two groups: continuation of the immunotherapy or observation without further treatment.

The decision on which group the patient is placed in is made randomly to ensure unbiased results in the study.

If assigned to the continuation group, the patient continues to receive nivolumab and ipilimumab infusions. The frequency and dosage remain consistent with the initial treatment phase.

The continuation phase lasts until there is evidence of disease progression or the patient experiences significant side effects that require discontinuation of the treatment.

If assigned to the observation group, the patient does not receive further treatment with nivolumab and ipilimumab.

The patient’s health and disease status are monitored regularly to track any changes or progression.

Throughout the trial, regular follow-up visits are scheduled to assess the patient’s health, monitor for any side effects, and evaluate the effectiveness of the treatment.

These visits may include physical examinations, imaging tests such as CT or MRI scans, and laboratory tests to measure various health indicators.